This article is
- freely available
Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing
Generation Health, 130 Turner St., Waltham, MA 02453, USA
TESARO Inc., 1000 Winter St. Suite 3300, Waltham, MA 02451, USA
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, 1620 Tremont St., Suite 3030, Boston, MA 02120, USA
ZIOPHARM Oncology, Inc., 1 First Avenue, Parris Building, #34, Navy Yard Plaza, Boston, MA 02129, USA
CVS Caremark, One CVS Drive, Woonsocket, RI 02895, USA
* Author to whom correspondence should be addressed.
Received: 28 August 2012; in revised form: 1 October 2012 / Accepted: 10 October 2012 / Published: 17 October 2012
Abstract: HMG-CoA reductase inhibitors, commonly known as statins, are some of the most widely prescribed medications worldwide and have been shown to be effective at lowering cholesterol in numerous long-term prospective trials, yet there are significant limitations to their use. First, patients receiving statin therapy have relatively low levels of medication adherence compared with other drug classes. Next, numerous statin formulations are available, each with its own unique safety and efficacy profile, and it may be unclear to prescribers which treatment is optimal for their patients. Finally, statins have class-wide side effects of myopathy and rhabdomyolysis that have resulted in a product recall and dosage limitations. Recent evidence suggests that two genomic markers, KIF6 and SLCO1B1, may inform the therapy choice of patients initiating statins. Given the prevalence of statin usage, their potential health advantages and their overall cost to the healthcare system, there could be significant clinical benefit from creating personalized treatment regimens. Ultimately, if this approach is effective it may encourage higher adoption of generic statins when appropriate, promote adherence, lower rates of myopathy, and overall achieve higher value cardiovascular care. This paper will review the evidence for personalized prescribing of statins via KIF6 and SLCO1B1 and consider some of the implications for testing these markers as part of routine clinical care.
Keywords: statins; adherence; myopathy; KIF6; SLCO1B1
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Canestaro, W.J.; Brooks, D.G.; Chaplin, D.; Choudhry, N.K.; Lawler, E.; Martell, L.; Brennan, T.; Wassman, E.R. Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing. J. Pers. Med. 2012, 2, 158-174.
Canestaro WJ, Brooks DG, Chaplin D, Choudhry NK, Lawler E, Martell L, Brennan T, Wassman ER. Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing. Journal of Personalized Medicine. 2012; 2(4):158-174.
Canestaro, William J.; Brooks, David G.; Chaplin, Donald; Choudhry, Niteesh K.; Lawler, Elizabeth; Martell, Lori; Brennan, Troyen; Wassman, E. Robert. 2012. "Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing." J. Pers. Med. 2, no. 4: 158-174.